Abstract
Background Persons Living with HIV (PLHIV) receiving antiretroviral therapy have increased risk of cardiovascular disease (CVD). Integration of services for hypertension (HTN), the primary CVD risk factor, into HIV clinics is recommended in Uganda. Our prior work demonstrated multiple gaps in implementation of integrated HTN care along the HIV treatment cascade. In this study, we sought to explore barriers to, and facilitators of, integrating HTN screening and treatment into HIV clinics in Eastern Uganda.
Methods We conducted a qualitative study at three HIV clinics with low, intermediate, and high HTN care cascade performance, which we classified based on our prior work. Guided by the Consolidated Framework for Implementation Research (CFIR), we conducted semi-structured interviews with health services managers, health care providers and hypertensive PLHIV (n=83). Interviews were transcribed verbatim. Three qualitative researchers used both deductive (CFIR model-driven) and inductive (open coding) methods to develop relevant codes and themes. Ratings were performed to determine valence and strengths of each CFIR construct regarding influencing HTN/HIV integration.
Results Of the 39 CFIR constructs assessed, 17 were relevant to either barriers or facilitators to HTN/HIV integration. Six constructs strongly distinguished performance and were barriers, three of which were in the Inner setting (Organizational Incentives & Rewards, Available Resources, Access to Knowledge & Information); two in Characteristics of individuals (Knowledge & Beliefs about the Intervention and Self-efficacy) and one in Intervention characteristics (Design Quality & Packaging). Four additional constructs were weakly distinguishing and negatively influenced HTN/HIV integration. There were four facilitators for HTN/HIV integration related to the intervention (Relative advantage, Adaptability, Complexity and Compatibility). The remaining four constructs negatively influenced HTN/HIV integration but were non-distinguishing.
Conclusion Using the CFIR, we have shown that while there are modifiable barriers to HTN/HIV integration in the Inner setting, Outer setting, Characteristics of individuals and implementation Process, HTN/HIV integration is of interest to patients, health care providers and managers. Improving access to HTN care among PLHIV will require overcoming barriers and capitalizing on the facilitators using a health system strengthening approach. These findings are a springboard for designing contextually appropriate interventions for HTN/HIV integration in low- and middle-income countries.
Contribution to the literature
We used the widely used and validated CFIR to assess the HIV program for HTN/HIV integration.
To our knowledge, this is the first study to explore barriers and facilitators to integrating hypertension screening and treatment into HIV clinics using the CFIR.
The barriers and facilitators identified are a basis for designing contextualized implementation interventions for HTN/HIV integration in Uganda and other LMIC using a health system strengthening approach.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was a qualitative study and we did not have to register it as a clinical trial.
Funding Statement
Research reported in this manuscript was supported by the Fogarty International Center and the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) under the Global Health Equity Scholars Consortium at Yale University (D43TW010540). Dr. Martin Muddu was also supported by the Fogarty International Center of the NIH under Award Number D43 TW010037. Dr. Ssinabulya Isaac was supported by the Nurture fellowship Grant Number D43TW010132. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funder had no role in the study design, data collection, analysis or interpretation. Martin Muddu had full access to all the data and had the final responsibility for the decision to submit the manuscript for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
List of abbreviations
- CFIR
- Consolidated Framework for Implementation Research
- HTN
- Hypertension
- PLHIV
- Persons Living with HIV
- CVD
- Cardiovascular Disease
- ART
- Antiretroviral Therapy
- WHO
- World Health Organization
- MoH
- Ministry of Health
- FGD
- Focus group discussion
- KII
- Key Informant Interview
- IDI
- In-depth interview
- DHO
- District Health Officer
- DHT
- District Health Team
- LMICs
- Low-and Middle Income Countries
